TISIDB

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm Cytoplasm, cytoskeleton, spindle Midbody Note=Nuclear localization observed during interphase (PubMed:16431929). Nuclear localization triggered by entry into mitosis (PubMed:16648480). Cytoplasmic in interphase (PubMed:16648480). Cytoplasmic in metaphase cells (PubMed:16431929). From prophase to metaphase, accumulates at the developing spindle poles and their associated microtubules. During anaphase, accumulates at the spindle midzone. Localization to the central spindle and midbody during anaphase is dependent upon PRC1 and CIT presence. In cells ready to undergo abscission, concentrates at the contractile ring.
Domain	PF00498 FHA domain PF00225 Kinesin motor domain PF16183 Kinesin-associated
Function	Microtubule motor protein that binds to microtubules with high affinity through each tubulin heterodimer and has an ATPase activity (By similarity). Plays a role in many processes like cell division, cytokinesis and also in cell proliferation and apoptosis (PubMed:24784001, PubMed:16648480). During cytokinesis, targets to central spindle and midbody through its interaction with PRC1 and CIT respectively (PubMed:16431929). Regulates cell growth through regulation of cell cycle progression and cytokinesis (PubMed:24854087). During cell cycle progression acts through SCF-dependent proteasomal ubiquitin-dependent protein catabolic process which controls CDKN1B degradation, resulting in positive regulation of cyclins, including CCNE1, CCND1 and CCNB1 (PubMed:24854087). During late neurogenesis, regulates the cerebellar, cerebral cortex and olfactory bulb development through regulation of apoptosis, cell proliferation and cell division (By similarity). Also is required for chromosome congression and alignment during mitotic cell cycle process (PubMed:15843429). Regulates cell spreading, focal adhesion dynamics, and cell migration through its interaction with RADIL resulting in regulation of RAP1A-mediated inside-out integrin activation by tethering RADIL on microtubules (PubMed:23209302).

> Gene Ontology [ TOP ]
Biological Process	GO:0000070 mitotic sister chromatid segregation GO:0000082 G1/S transition of mitotic cell cycle GO:0000086 G2/M transition of mitotic cell cycle GO:0000819 sister chromatid segregation GO:0000910 cytokinesis GO:0001558 regulation of cell growth GO:0007018 microtubule-based movement GO:0007059 chromosome segregation GO:0007067 mitotic nuclear division GO:0007080 mitotic metaphase plate congression GO:0007265 Ras protein signal transduction GO:0007272 ensheathment of neurons GO:0007346 regulation of mitotic cell cycle GO:0008366 axon ensheathment GO:0010389 regulation of G2/M transition of mitotic cell cycle GO:0010498 proteasomal protein catabolic process GO:0016049 cell growth GO:0021537 telencephalon development GO:0021543 pallium development GO:0021549 cerebellum development GO:0021575 hindbrain morphogenesis GO:0021587 cerebellum morphogenesis GO:0021680 cerebellar Purkinje cell layer development GO:0021681 cerebellar granular layer development GO:0021683 cerebellar granular layer morphogenesis GO:0021685 cerebellar granular layer structural organization GO:0021692 cerebellar Purkinje cell layer morphogenesis GO:0021693 cerebellar Purkinje cell layer structural organization GO:0021695 cerebellar cortex development GO:0021696 cerebellar cortex morphogenesis GO:0021698 cerebellar cortex structural organization GO:0021700 developmental maturation GO:0021761 limbic system development GO:0021766 hippocampus development GO:0021772 olfactory bulb development GO:0021846 cell proliferation in forebrain GO:0021987 cerebral cortex development GO:0021988 olfactory lobe development GO:0022037 metencephalon development GO:0030705 cytoskeleton-dependent intracellular transport GO:0030900 forebrain development GO:0030902 hindbrain development GO:0031146 SCF-dependent proteasomal ubiquitin-dependent protein catabolic process GO:0031333 negative regulation of protein complex assembly GO:0031589 cell-substrate adhesion GO:0031641 regulation of myelination GO:0032147 activation of protein kinase activity GO:0032465 regulation of cytokinesis GO:0032467 positive regulation of cytokinesis GO:0032486 Rap protein signal transduction GO:0032487 regulation of Rap protein signal transduction GO:0033622 integrin activation GO:0033623 regulation of integrin activation GO:0033624 negative regulation of integrin activation GO:0033674 positive regulation of kinase activity GO:0034446 substrate adhesion-dependent cell spreading GO:0042552 myelination GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043254 regulation of protein complex assembly GO:0043523 regulation of neuron apoptotic process GO:0043524 negative regulation of neuron apoptotic process GO:0044770 cell cycle phase transition GO:0044772 mitotic cell cycle phase transition GO:0044839 cell cycle G2/M phase transition GO:0044843 cell cycle G1/S phase transition GO:0045787 positive regulation of cell cycle GO:0045860 positive regulation of protein kinase activity GO:0046578 regulation of Ras protein signal transduction GO:0048469 cell maturation GO:0048532 anatomical structure arrangement GO:0050000 chromosome localization GO:0051056 regulation of small GTPase mediated signal transduction GO:0051302 regulation of cell division GO:0051303 establishment of chromosome localization GO:0051310 metaphase plate congression GO:0051402 neuron apoptotic process GO:0051640 organelle localization GO:0051656 establishment of organelle localization GO:0051781 positive regulation of cell division GO:0061351 neural precursor cell proliferation GO:0070997 neuron death GO:0090068 positive regulation of cell cycle process GO:0098813 nuclear chromosome segregation GO:1901214 regulation of neuron death GO:1901215 negative regulation of neuron death GO:1901987 regulation of cell cycle phase transition GO:1901990 regulation of mitotic cell cycle phase transition GO:1902749 regulation of cell cycle G2/M phase transition GO:1902806 regulation of cell cycle G1/S phase transition GO:1903429 regulation of cell maturation GO:2000045 regulation of G1/S transition of mitotic cell cycle
Molecular Function	GO:0003774 motor activity GO:0003777 microtubule motor activity GO:0008017 microtubule binding GO:0008574 ATP-dependent microtubule motor activity, plus-end-directed GO:0015631 tubulin binding GO:0016887 ATPase activity GO:0030165 PDZ domain binding GO:1990939 ATP-dependent microtubule motor activity
Cellular Component	GO:0005819 spindle GO:0005871 kinesin complex GO:0005874 microtubule GO:0005875 microtubule associated complex GO:0030496 midbody GO:0051233 spindle midzone

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-195258: RHO GTPase Effectors R-HSA-5625900: RHO GTPases activate CIT R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KIF14 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KIF14 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KIF14 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.621	0.0254
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.519	0.458
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.7	0.242
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.126	0.809
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.054	0.972
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.208	0.922
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.021	0.958
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.815	0.519
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	1.098	0.364
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.162	0.706
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.113	0.847
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.475	0.000649

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KIF14 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	4.1	7	0.339
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	5.1	6	0.373
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	0	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KIF14. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KIF14. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KIF14. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KIF14. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KIF14 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KIF14 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KIF14
Name	kinesin family member 14
Aliases	KIAA0042; MKS12; Kinesin-like protein KIF14
Chromosomal Location	1q32.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KIF14 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse KIF14